INDUSTRY × Pancreatic Neoplasms × Dermatologic × Clear all
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
NCT02568267 2026-05-27

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
NCT05461430 2026-04-13

TraveraRTGx

Travera Inc

Completed
72 enrolled
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT06242470 2026-02-05

A Study of MGC026 in Participants With Advanced Solid Tumors

MacroGenics

Phase 1 Recruiting
250 enrolled
NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Second Life Therapeutics

Phase 1/2 Not yet recruiting
60 enrolled
NCT03452774 2025-10-28

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio, Inc.

Recruiting
50,000 enrolled
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

Phase 1/2 Active not recruiting
98 enrolled
NCT04068896 2025-05-29

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NGM Biopharmaceuticals, Inc

Phase 1/2 Completed
89 enrolled 21 charts
NCT04140526 2025-05-23

PRESERVE-001

OncoC4, Inc.

Phase 1/2 Active not recruiting
733 enrolled
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Kymab Limited

Phase 1/2 Terminated
222 enrolled 49 charts
NCT04028479 2024-12-18

ROOT

Taproot Health

Completed
167 enrolled
NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled